Last reviewed 2026-05-15 · How we verify

Junmin Li — Portfolio Competitive Intelligence Brief

Junmin Li pipeline: 0 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Junmin Li:

• Junmin Li pipeline updates — RSS
• Junmin Li pipeline updates — Atom
• Junmin Li pipeline updates — JSON

Cite this brief

Drug Landscape (2026). Junmin Li — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/junmin-li. Accessed 2026-05-15.

Related

• Junmin Li full company profile
• All CI briefs
• Build a custom feed